ERBB2 and neoplasm: Several issues had been highlighted in GEA as possible explanations, like the tumor heterogeneity (8) or the presence of molecular mechanisms of resistance to anti-HER2 therapy, such as changes in the tridimensional receptor structures, the co-expression of other transmembrane receptors, or the activation of downstream signaling effectors (9).